FIELD: medicine.
SUBSTANCE: method involves vaccinating patients with embryonic antitumor modulator agent containing wide range of oncofetal antigens. Vaccination is carried out in subcutaneous application once a year at a dose of 0.02-0.04 mg/kg. The preferential dose is equal to 0.03 mg/kg of body weight.
EFFECT: high stability of the agent; stimulated antitumor resistance.
4 cl, 2 dwg, 4 tbl
